This has been completed in HCT-116 CRC cells [237] and MCF7 breast cancer cells [238] treated with conventional chemotherapies and in HCT-116, HT-29, and KM12C CRC cells treated with MEK, TRK, tyrosine kinase, RET, BRAF, PARP, PI3K, and GSK-3 inhibitors as well as Imipridones [239]. Here, MAP2K7 is linked to breast cancer.